
The MPET Lab (IBUB) participates in an ambitious consortium to design drugs to enhance the immune response against cancer
The project will develop new compounds against three therapeutic targets linked to tumor inflammation and will study their combined use to improve immunotherapies. The initiative has been funding with more than 2.5 million euros and is part of a Retos Colaboración call. The Molecular Pharmacology and Experimental Therapeutics (MPET) research group, led by Marçal Pastor-Anglada,